The Lyme Disease drugs in development market research report provides comprehensive information on the therapeutics under development for Lyme Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Lyme Disease. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Lyme Disease and features dormant and discontinued products.

GlobalData tracks 25 drugs in development for Lyme Disease by 24 companies/universities/institutes. The top development phase for Lyme Disease is preclinical with 11 drugs in that stage. The Lyme Disease pipeline has 21 drugs in development by companies and four by universities/ institutes. Some of the companies in the Lyme Disease pipeline products market are: Moderna, University of North Dakota and Intravacc.

The key targets in the Lyme Disease pipeline products market include Outer Surface Protein A (ospA), Fibronectin (Cold Insoluble Globulin or FN1), and Corticotropin Releasing Factor Receptor 2 (Corticotropin Releasing Hormone Receptor 2 or CRHR2).

The key mechanisms of action in the Lyme Disease pipeline product include Outer Surface Protein A (ospA) Inhibitor with two drugs in Phase I. The Lyme Disease pipeline products include six routes of administration with the top ROA being Oral and eight key molecule types in the Lyme Disease pipeline products market including Small Molecule, and Subunit Vaccine.

Lyme Disease overview

Lyme disease is a bacterial infection transmitted by a tick. Lyme disease is caused by the bacterium Borrelia burgdorferi. Symptoms include rash, fever, chills, fatigue, body aches, and headache. Risk factors include age, gender, and geographic location. Treatment includes antibiotics.

For a complete picture of Lyme Disease’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.